Hyundai Bioscience Co., Ltd.

Equities

A048410

KR7048410005

Personal Products

End-of-day quote Korea S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
19,860 KRW -0.30% Intraday chart for Hyundai Bioscience Co., Ltd. -1.93% -23.91%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil CI
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer CI
Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer CI
Hyundai Bioscience to Carry Out Global Clinical Tests Aimed At Treating All Serotypes of Dengue Virus Infection CI
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 32.47% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion. CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Vector Inc. completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Vector Inc. agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. for KRW 13.7 billion. CI
Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hyundai Bioscience Co., Ltd. Launches CP-COV03 Phase 2 Clinical Trials CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills MT
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Hyundai Bioscience Co., Ltd. Announces Oral Antiviral Drug from Korea May Be A Problem Solver for Covid-19 CI
Hyundai Bioscience Announces CNPharm Publishes a Research Paper on Successful Repurposing of Niclosamide for COVID-19 Treatment by Using a Drug Delivery System CI
Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19 CI
Hyundai Bioscience Co., Ltd. announced that it has received KRW 32 billion in funding from a group of investors CI
Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 32 billion in funding from a group of investors CI
Hyundai Bioscience Co., Ltd. Unveils New Cancer Treatment That Offers Tumor Elimination Without Painful Side Effects CI
Hyundai Bioscience Co., Ltd. announced that it has received funding from CnPharm Co., Ltd. and another investor CI
Chart Hyundai Bioscience Co., Ltd.
More charts
HYUNDAI BIOSCIENCE CO., LTD. it is a Korea-based company mainly engaged in the manufacturing and sale of bio cosmetics and hair tonic products. It develops functional daily necessities such as shampoos, mask packs, creams, and tumor-targeted drug. The Company also sells liquid crystal display (LCD) monitors and digital signage display products. The Company distributes its products in domestic market, as well as to the overseas markets, including Europe, America and Japan.
More about the company
  1. Stock Market
  2. Equities
  3. A048410 Stock
  4. News Hyundai Bioscience Co., Ltd.
  5. South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills